SEC Comment Letter 0000000000-23-012526 to Phathom Pharmaceuticals, Inc. (PHAT) (CIK 0001783183) (PHAT)

Phathom Pharmaceuticals, Inc. (PHAT) (CIK 0001783183)
Date: Nov. 15, 2023 · CIK: 0001783183 · Accession: 0000000000-23-012526

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-275431

Date

November 15, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Phathom Pharmaceuticals, Inc. (PHAT) (CIK 0001783183)

Letter

United States securities and exchange commission logo November 15, 2023 Terrie Curran President and Chief Executive Officer Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 Re:Phathom Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 9, 2023 File No. 333-275431 Dear Terrie Curran: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anthony A. Gostanian, Esq.

Show Raw Text

United States securities and exchange commission logo
November 15, 2023
Terrie Curran
President and Chief Executive Officer
Phathom Pharmaceuticals, Inc.
100 Campus Drive, Suite 102
Florham Park, New Jersey 07932
Re:Phathom Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 9, 2023
File No. 333-275431
Dear Terrie Curran:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Anthony A. Gostanian, Esq.

SecProbe.io